- Investment exceeds PLN 100 mln.
- Completion planned for 2019.
- Capacity increase to 110,000 tonnes annually.
- Focus on pharmaceutical-grade sodium bicarbonate.
Investment and Modernization
Work is underway in Germany to modernize and expand sodium bicarbonate production lines, enabling the production of dialysis soda, a specialized product used in kidney disease treatment. The project, valued at over PLN 100 million, is set for completion in 2019.
Production Capacity
The investment includes expanding soda centrifugation, drying, sifting, and decarbonization nodes, as well as increasing warehouse space. This will allow for an annual production capacity of up to 110,000 tonnes of pharmaceutical-grade sodium bicarbonate at the Stassfurt plants.
Quality and Certification
Both German and Polish plants have obtained GMP certificates, essential for manufacturing dialysis soda. This product requires the highest degree of purity and strictly defined granulation, verified by pharmaceutical companies through periodic audits.
Market Dynamics
The dialysis soda market is expected to grow by 5-10% annually due to increased accessibility of haemodialysis treatments, healthcare improvements, and higher healthcare expenditures in developing countries. Currently, 10% of the global population suffers from chronic kidney disease, with over 2 million people undergoing dialysis, a number expected to double by 2020.
Broader Applications
Pharmaceutical-grade sodium bicarbonate has various applications, including effervescent tablets, medications, dietary supplements, toothpaste, and wellness products. The expanded production will also cater to the food and feed industries, as well as the manufacture of detergents and other chemical products.
